Diagnostic Evaluation of Dementia with Lewy Bodies Using a Multimodal Approach
Recruiting
Observational Study
Lewy Bodies Disease
Alzheimer Disease
Cognitive Impairment
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 55 – 85
- Sex
- Any
- Study type
- Observational
- Participants needed
- 130 (estimated)
- Sponsor
- Assistance Publique - Hôpitaux de Paris · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Dementia with Lewy body disease (DLB) is the second leading cause of degenerative cognitive disorder after Alzheimer's disease (AD). Its variable clinical expression makes diagnosis difficult. To date, there is no validated DLB diagnostic biomarker, despite several biomarkers in development (EEG, MRI, biology).
Studies have shown that an improvement in diagnostic performance could be obtained by …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria for DLB ant AD patients:
* Neuropsychological assessment possible (good level in French language, absence of visual/auditory deficit limiting the cognitive assessment)
* Dementia with Lewy bodies according to the revised criteria of Mc Keith 2017 or probable AD defined according …
Contacts